EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-world use of PSMA imaging in metastatic castration-sensitive prostate cancer: Findings from the CAPRI-3 registry

K J M van der Velden, D Bosch, Z Vassilev, A M Bergman, A C M van den Bergh, M J van der Doelen, A J M van den Eertwegh, J Lavalaye, R J A van Moorselaar, D M Somford, M Tascilar, A Raval und 3 weitere

European Journal of Nuclear Medicine and Molecular Imaging · 2026

DOI: 10.1007/s00259-026-08050-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2026. Verfasst von K J M van der Velden und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Radboud University Medical Center, Geert Grooteplein Zuid 10, PO Box: 9101, 6525, Nijmegen, GA, The Netherlands. Kim.vanderVel…. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Registries, Antigens, Surface, Glutamate Carboxypeptidase II. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Since 2019, EAU guidelines recommend PSMA-PET/CT for staging high-risk prostate cancer. However, real-world data on its uptake and association with disease characteristics and outcomes in metastatic castration-sensitive prostate cancer (mCSPC) remains limited. We evaluated real-world PSMA-PET/CT use versus conventional imaging (CI).

Methods

This retrospective study included 3,644 mCSPC patients (2016–2021) from 19 hospitals in the Dutch CAPRI-3 registry. Staging within 90 days of diagnosis was classified as CI-only (CT, bone scintigraphy, and/or MRI) or PSMA-PET (± CI).

Results

Most patients were staged with CI-only (63%), but PSMA-PET use rose from 8% in 2016 to 62% in 2021. PSMA-PET-staged patients were younger (72 vs. 76 years) and had significantly lower tumour burden (27% vs. 45% high-volume), more nodal-only disease, and were more likely to have metachronous presentation (29% vs. 22%, all P < 0.001). In the PSMA-PET group, 42% received ADT plus targeted therapy and 23% ADT monotherapy (vs. 45% ADT monotherapy in CI-only). Median overall survival was significantly longer in the PSMA-PET cohort (78.3 vs. 40.0 months).

Conclusion

There has been an increasing trend toward the use of PSMA PET/CT for staging mCSPC in recent years, identifying a population with more favourable disease characteristics and a more favourable prognosis. This shift in patient characteristics, driven by stage migration (the Will Rogers phenomenon), influences clinical management by enabling more refined patient selection for conservative or targeted therapies. Consequently, accounting for lead-time and selection bias is essential when comparing survival outcomes in the PSMA PET/CT era.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron Emission Tomography Computed TomographyRegistriesAntigens, SurfaceGlutamate Carboxypeptidase IIHumansMaleAgedNeoplasm MetastasisRetrospective StudiesAged, 80 and overNeoplasm StagingMiddle Aged

Stichwörter der Autor:innen

Computer tomographyImagingMetastatic castration-sensitive prostate cancerPSMA-PET/CTReal-world evidence

Substanzen

Antigens, SurfaceFOLH1 protein, humanGlutamate Carboxypeptidase II

Autor:innen und Institutionen

  • Department of Urology, Radboud University Medical Center, Geert Grooteplein Zuid 10, PO Box: 9101, 6525, Nijmegen, GA, The Netherlands. Kim.vanderVelden@radboudumc.nl.
  • Department of Urology, Radboud University Medical Center, Geert Grooteplein Zuid 10, PO Box: 9101, 6525, Nijmegen, GA, The Netherlands.
  • Bayer Healthcare Pharmaceuticals, Healthcare Pharmaceuticals, Whippany, NJ, USA.
  • Department of Medical Oncology, Netherlands Cancer Institute (NKI), Amsterdam, Netherlands.
  • Department of Medical Oncology, Amsterdam University Medical Center, Amsterdam, Netherlands.
  • Department of Radiation Oncology, Antoni Van Leeuwenhoek (AVL), Amsterdam, Netherlands.

Förderung

  • National Science Foundation

Zitieren

APA

van der Velden, K. J. M., Bosch, D., Vassilev, Z., Bergman, A. M., van den Bergh, A. C. M., van der Doelen, M. J., van den Eertwegh, A. J. M., Lavalaye, J., van Moorselaar, R. J. A., Somford, D. M., Tascilar, M., Raval, A., Groot, C. A. U., Kuppen, M. C. P., & van Oort, I. M. (2026). Real-world use of PSMA imaging in metastatic castration-sensitive prostate cancer: Findings from the CAPRI-3 registry. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-026-08050-7

Vancouver

van der Velden KJM, Bosch D, Vassilev Z, Bergman AM, van den Bergh ACM, van der Doelen MJ, et al. Real-world use of PSMA imaging in metastatic castration-sensitive prostate cancer: Findings from the CAPRI-3 registry. European Journal of Nuclear Medicine and Molecular Imaging. 2026. doi:10.1007/s00259-026-08050-7

BibTeX
@article{vanderVelden2026,
  author = {van der Velden, K J M and Bosch, D and Vassilev, Z and Bergman, A M and van den Bergh, A C M and van der Doelen, M J and van den Eertwegh, A J M and Lavalaye, J and van Moorselaar, R J A and Somford, D M and Tascilar, M and Raval, A and Groot, C A Uyl-de and Kuppen, M C P and van Oort, I M},
  title = {Real-world use of PSMA imaging in metastatic castration-sensitive prostate cancer: Findings from the CAPRI-3 registry},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2026},
  doi = {10.1007/s00259-026-08050-7}
}
Kostenlos starten →